Eurobio Scientific Société anonyme (ALERS) Fair Value & Analysis
Healthcare · FR · Market cap €219M
Fair value as of: Jun 24, 2026
Analysis
Eurobio Scientific Société anonyme (ALERS) currently trades at €22.20, while our model-based Fair Value estimate is €14.37 — implying the stock looks roughly 35.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Eurobio Scientific Société anonyme engages in the design, development, and commercialization of in vitro diagnostics products in the areas of transplantation, immunology, infectious diseases, life-science, and oncology. It commercializes media for the transportation and preservation of cornea grafts, as well as a device to facilitate the corresponding surgery; AlloMap, for heart transplant monitoring; cell culture media, molecular biology reagents, and proprietary antibodies; TQS (Tetanus Quick Stick) for the evaluation of patients' immune status against tetanus; and EBX molecular biology range, which includes a range of tests for identifying various pathogens responsible for infectious diseases. The company also develops other diagnostic products using molecular biology. The company was formerly known as Diaxonhit and changed its name to Eurobio Scientific Société anonyme in June 2018. Eurobio Scientific Société anonyme was incorporated in 1997 and is headquartered in Les Ulis, Fra…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Eurobio Scientific Société anonyme (ALERS) undervalued?
What is the fair value of ALERS?
What is the quality score of ALERS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.